Buying AI regulatory software is fundamentally different from procuring an EDC or eTMF. Those platforms store information humans create. AI tools generate protocol drafts, ICFs, investigator brochures, and clinical study reports that may reach regulatory agencies. That distinction creates compliance exposure that extends back to the sponsor. Under ICH E6(R3), finalized in January 2025 and adopted by FDA in September 2025, ultimate responsibility for trial conduct remains with the sponsor even when activities are delegated to vendors. If a KScribe-generated protocol section contains an error that reaches an IND, the sponsor owns that error, not the vendor. The FDA and EMA issued joint AI guiding principles in January 2026, adding a second layer of questions to procurement conversations: validation, model governance, audit trail architecture, data custody, hallucination controls. Critical questions include whether the validation package covers AI-specific risks like hallucination scenarios, whether the system produces submission-ready audit trails capturing model version and generation timestamp, and how the platform maintains consistency across document sets. For AI platforms generating regulatory content, GCP inspectors will likely request documentation showing how outputs were produced and reviewed.